ReviewHuman vaccines & immunotherapeutics2012
Plasmid IL-12 electroporation in melanoma.
Review in Human vaccines & immunotherapeutics, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 45 citations in OpenAlex.
- Intratumoral Plasmid IL12 Electroporation Therapy in Patients with Advanced Melanoma Induces Systemic and Intratumoral T-cell Responses.Cancer immunology research · 2020Trial
- Development of an Advanced Drug Delivery System for Protein- and Peptide-Based Therapeutics.Current pharmaceutical design · 2026Review
- Intratumoral expression of IL-12 and CD40 ligand (CD154) from plasmids generates antitumor responses that eliminate tumoral T regs.Scientific reports · 2025Article
- The Antagonistic and Synergistic Role of FePharmaceuticals (Basel, Switzerland) · 2024Article
- Review
- Antitumor Activities of Interleukin-12 in Melanoma.Cancers · 2022Review
- Chemotherapy and Physical Therapeutics Modulate Antigens on Cancer Cells.Frontiers in immunology · 2022Review
- Intratumoral Delivery of Plasmid IL12 Via Electroporation Leads to Regression of Injected and Noninjected Tumors in Merkel Cell Carcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2020Article
- A Novel Method for Controlled Gene Expression via Combined Bleomycin and Plasmid DNA Electrotransfer.International journal of molecular sciences · 2019Article
- IFN-γ: A cytokine at the right time, is in the right place.Seminars in immunology · 2019Review
- Active Immunoprophylaxis and Vaccine Augmentations Mediated by a Novel Plasmid DNA Formulation.Human gene therapy · 2019Article
- Intradermal DNA vaccination combined with dual CTLA-4 and PD-1 blockade provides robust tumor immunity in murine melanoma.PloS one · 2019Article
- Improving therapeutic efficacy of IL-12 intratumoral gene electrotransfer through novel plasmid design and modified parameters.Gene therapy · 2018Article
- Article
- Electrotransfer of Different Control Plasmids Elicits Different Antitumor Effectiveness in B16.F10 Melanoma.Cancers · 2018Article
- Upregulation of DNA Sensors in B16.F10 Melanoma Spheroid Cells After Electrotransfer of pDNA.Technology in cancer research & treatment · 2018Article
- Advancements in DNA vaccine vectors, non-mechanical delivery methods, and molecular adjuvants to increase immunogenicity.Human vaccines & immunotherapeutics · 2017Review
- Advances in the development of intralesional therapies for melanoma.Melanoma management · 2016Review
- Rationale for immune-based therapies in Merkel polyomavirus-positive and -negative Merkel cell carcinomas.Immunotherapy · 2016Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intratumoral gene electroporation uses electric charges to facilitate entry of plasmid DNA into cells in a reproducible and highly efficient manner, especially to accessible sites such as cutaneous and subcutaneous melanomas. Effective for locally treated disease, electroporation of plasmid DNA encoding interleukin-12 can also induce responses in untreated distant disease, suggesting that adaptive immune responses are being elicited that can target melanoma-associated antigens. In vivo electroporation with immunomodulatory cytokine DNA is a promising approach that can trigger systemic anti-tumor immune responses without the systemic toxicity associated with intravenous cytokine delivery and potentially offer complete long-term tumor regression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.